Hyperfine SPAC Presentation Deck

Transaction overview Sources, uses and pro forma ownership Sources of Funds ($M) Cash in Trust¹ Target Shareholders Equity Rollover Private Placement Target Cash² Sponsor Founder Shares Total Sources Pro Forma Valuation ($M)5 Illustrative Share Price Fully Diluted Shares Outstanding (M)4 Equity Value + Debt - Cash Enterprise Value 2023 Revenue 2023 Revenue Multiple $207.0 $564.8 $126.1 $66.0 $57.9 $1,021.8 $10.00 95.6 $956.0 $0.06 $374.7 $581.3 $54.2 10.7x Uses of Funds ($M) Equity Issued to Target Shareholders Cash to Balance Sheet³ Estimated Transaction Costs Sponsor Founder Shares Payment of Loan Payable Total Uses Pro Forma Valuation5 HealthCor Catalio Founder Shares 6.0% PIPE Investor Shares 13.2% Health Cor Catalio Public Shares 21.7% 6.0% 13.2% 21.7% 48.0% 11.1% $564.8 $374.7 $24.2 $57.9 $0.2 $1,021.8 Hyperfine Equity Rollover 48.0% Liminal Equity Rollover 11.1% 6 © 2021 Hyperfine, Inc. 1: Assumes no redemptions. 2: Assumed cash on Hyperfine/Liminal balance sheet at closing of the transaction. 3: Comprised of $207.0 million from the SPAC trust fund, $126.1 million from PIPE investors and $65.8 million from Hyperfine/Liminal balance sheet (assumed cash on Hyperfine/Liminal balance sheet at closing of the transaction), less $24.2 million transaction expenses. 4: Estimated fully diluted shares outstanding based on (i) Hyperfine shares (45.9M); (ii) Liminal shares (10.6M); (iii) PIPE shares (12.6M); (iv) Health Cor Catalio public shares (20.7M); (v) Health Cor Catalio Sponsor shares (5.8M) 5: Valuation excludes any impact from potential earnouts 6: Reflects estimated debt balance following the closing of the transaction HYPERFINE

View entire presentation